Two companies, Curis and Autolus, have seen their shares rise sharply on promising abstracts of early data to be presented at the European Hematology Association meeting, being held from 9-17 June.
Curis And Autolus Rise On EHA Abstract Data
Potential Advances In AML and NHL
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.
More from Business
More from Scrip
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.
• By
CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.